Stony Brook University School of Medicine, Health Sciences Tower, Level 4, Room 184, Stony Brook, NY 11794-8430;
Am J Clin Pathol. 2014 Apr;141(4):462-77. doi: 10.1309/AJCPQN8GZ8SILKGN.
Triple-negative breast cancer is regarded as an aggressive disease that affects a young patient population and for which effective targeted therapy is not yet available.
Intense efforts have been made to gain a better understanding of this heterogeneous group of tumors from the histologic to the genomic and molecular levels.
Progress has been made, including the ability to subtype these tumors and the discovery of biomarkers toward which current therapeutic efforts are focused. Many novel targets under exploration have the potential to affect the clinical course of this disease.
This article reviews the current concepts regarding the clinicopathologic features of triple-negative breast carcinoma, its histologic subtypes, molecular classification, the prognostic and therapeutic potential of biomarkers, and emerging targeted therapies.
三阴性乳腺癌被认为是一种侵袭性疾病，影响年轻患者群体，目前尚无有效的靶向治疗方法。
从组织学、基因组和分子水平上，人们已经做出了巨大努力来更好地理解这组异质性肿瘤。
已经取得了进展，包括对这些肿瘤进行亚型分类的能力，以及发现了当前治疗重点关注的生物标志物。许多正在探索的新靶点有可能影响这种疾病的临床过程。
本文综述了三阴性乳腺癌的临床病理特征、组织学亚型、分子分类、生物标志物的预后和治疗潜力以及新兴的靶向治疗方法的最新概念。
